
Opinion|Videos|April 9, 2025
Advances in the Understanding of Hypercortisolism
Experts discuss the long-term health impacts of hypercortisolism, including unresolved comorbidities and increased mortality risk, the consequences of delayed diagnosis, and how the understanding of its clinical presentation has evolved.
Advertisement
Episodes in this series

Video content above is prompted by the following:How can hypercortisolism affect a patient’s long-term health and quality of life?
- Long-term risks remain for patients even if hypercortisolism remission is achieved, including incomplete resolution of comorbidities, reduced quality of life, and increased mortality risk.
- What are some of the consequences of a delayed or missed hypercortisolism diagnosis?
- Increased risk of cardiometabolic abnormalities, osteoporosis, and psychiatric disorders
- Increase in mortality rate compared with the general population
- How has our understanding of the clinical presentation of hypercortisolism evolved?
- Overt, hallmark symptoms and features vs nonspecific features and symptoms overlapping with chronic disease
Advertisement
Related to this article

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
RAPID: Etripamil Converts Two-Thirds of Recurrent PSVT Episodes After Ablation
3
Metformin May Lower Cardiac Dysfunction Risk During VEGF Inhibitor Therapy
4
Building Trust Into Community Kidney Screening, With David Van Wyck, MD
5

